Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Expected to Post Quarterly Sales of $2.57 Million

Analysts expect Reata Pharmaceuticals, Inc. (NASDAQ:RETAGet Rating) to post $2.57 million in sales for the current quarter, Zacks reports. Two analysts have issued estimates for Reata Pharmaceuticals’ earnings. The highest sales estimate is $3.13 million and the lowest is $2.00 million. Reata Pharmaceuticals reported sales of $2.22 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 15.8%. The firm is expected to issue its next earnings results on Monday, January 1st.

On average, analysts expect that Reata Pharmaceuticals will report full year sales of $6.31 million for the current financial year, with estimates ranging from $900,000.00 to $11.12 million. For the next financial year, analysts forecast that the company will report sales of $50.33 million, with estimates ranging from $29.57 million to $83.90 million. Zacks’ sales averages are a mean average based on a survey of analysts that that provide coverage for Reata Pharmaceuticals.

Reata Pharmaceuticals (NASDAQ:RETAGet Rating) last posted its earnings results on Tuesday, May 10th. The company reported ($2.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.26) by $0.23. Reata Pharmaceuticals had a negative net margin of 2,650.72% and a negative return on equity of 137.52%. The business had revenue of $0.91 million for the quarter, compared to analyst estimates of $1.55 million. During the same period last year, the business posted ($1.86) EPS. Reata Pharmaceuticals’s revenue was down 3.2% compared to the same quarter last year.

A number of analysts have weighed in on RETA shares. StockNews.com started coverage on shares of Reata Pharmaceuticals in a report on Thursday, March 31st. They issued a “sell” rating for the company. The Goldman Sachs Group raised shares of Reata Pharmaceuticals from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $34.00 to $91.00 in a report on Thursday, March 24th. Finally, LADENBURG THALM/SH SH reduced their price objective on shares of Reata Pharmaceuticals from $75.00 to $67.00 in a report on Wednesday, May 11th. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, Reata Pharmaceuticals presently has an average rating of “Hold” and an average price target of $64.17.

A number of hedge funds have recently made changes to their positions in RETA. FourThought Financial LLC increased its position in Reata Pharmaceuticals by 58.0% in the 3rd quarter. FourThought Financial LLC now owns 583 shares of the company’s stock valued at $58,000 after acquiring an additional 214 shares in the last quarter. Macquarie Group Ltd. increased its position in Reata Pharmaceuticals by 60.1% in the 3rd quarter. Macquarie Group Ltd. now owns 594 shares of the company’s stock valued at $60,000 after acquiring an additional 223 shares in the last quarter. US Bancorp DE increased its position in Reata Pharmaceuticals by 930.5% in the 1st quarter. US Bancorp DE now owns 1,824 shares of the company’s stock valued at $60,000 after acquiring an additional 1,647 shares in the last quarter. O Shaughnessy Asset Management LLC increased its position in Reata Pharmaceuticals by 6,360.0% in the 3rd quarter. O Shaughnessy Asset Management LLC now owns 646 shares of the company’s stock valued at $65,000 after acquiring an additional 636 shares in the last quarter. Finally, First Mercantile Trust Co. increased its position in Reata Pharmaceuticals by 20.6% in the 3rd quarter. First Mercantile Trust Co. now owns 721 shares of the company’s stock valued at $73,000 after acquiring an additional 123 shares in the last quarter. 73.55% of the stock is owned by hedge funds and other institutional investors.

Shares of Reata Pharmaceuticals stock opened at $28.78 on Friday. Reata Pharmaceuticals has a fifty-two week low of $20.24 and a fifty-two week high of $153.41. The firm has a fifty day moving average price of $30.96 and a two-hundred day moving average price of $40.41. The company has a market cap of $1.05 billion, a PE ratio of -3.45 and a beta of 1.25.

Reata Pharmaceuticals Company Profile (Get Rating)

Reata Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase 2 study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others.

Featured Stories

Get a free copy of the Zacks research report on Reata Pharmaceuticals (RETA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Reata Pharmaceuticals (NASDAQ:RETA)

Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.